John Irving Bell
Co-Founder at Oxagen Ltd.
John Irving Bell
John Irving Bell
Co-Founder at Oxagen Ltd.



John Irving Bell is affiliated with Academy of Medical Sciences, University of Oxford, Stanford University - School of Medicine, The Wellcome Trust Centre For Human Genetics, Oxford University Medical School, GHO Capital Partners LLP, Oxagen Ltd., Genomics England Ltd., Roche Holding AG, Immunocore Ltd., Immunocore Holdings Plc, Carrick Therapeutics Ltd., Hakluyt & Co. Ltd., Genomics England Ltd., Roche Ventures, Sensyne Health Plc, Atopix Therapeutics Ltd., Genentech, Inc., Avidex Ltd., F. Hoffmann-La Roche Ltd., Oxagen Ltd., AstraZeneca Plc, Powderject Pharmaceuticals Plc, Protemix Corp. Ltd., Oxford University Innovation Ltd., Oxford University Hospitals NHS Trust, The Precision Medicine Catapult, Rhodes Trust, The Gray Laboratory Cancer Research Trust, The Jenner Institute Laboratories, The Ewelme Almshouse Charity, Bill & Melinda Gates Foundation, Office for Strategic Co-ordination of Health Research, Medical Research Council, University of Oxford, The Rhodes Trust, Oxford Centre for Diabetes Endocrinology & Metabolism, The Oxford Health Alliance, GMEC Management Co. Ltd.